EMBL-EBI is a highly collaborative organisation and we value our work with other leading research institutes and industry partners. Our data services are run jointly with partners throughout the world, and our research groups play a key role in many projects of global significance. We are a partner in several of Europe’s emerging research infrastructures, and host the secretariat for ELIXIR, Europe's distributed infrastructure for life-science information.
Each of our research groups collaborates with partners worldwide on a range of projects, publishing in prestigious peer-reviewed journals and producing innovative, novel software databases and tools that are freely available to our users. Our many research collaborations are too numerous to list here, but we invite you to explore them on individual research group pages.
EMBL-EBI adopts a collaborative approach to its database service provision, serving as the European node for globally coordinated data collection and dissemination projects. Our core databases are produced in collaboration with other world leaders, including the NCBI (US), the National Institute of Genetics (Japan), the SIB Swiss Institute of Bioinformatics (Switzerland), the Wellcome Trust Sanger Institute (UK) and Cold Spring Harbor Laboratory (US). Our collaborations enable us to offer the world’s most comprehensive collection of molecular databases. See the full list of our major database collaborations for more details.
EMBL-EBI hosts the Technical Hub of ELIXIR, the distributed European infrastructure for biological information. The purpose of ELIXIR is to support research and its translation to medicine and the environment, the bio-industries and society. EMBL-EBI participates in several ELIXIR pilot actions and is a partner on CORBEL, which seeks to harmonise user access to life-science resources, and Excelerate, an initiative to fast-track the implementation of life-science data infrastructure. www.elixir-europe.org
The partnership between EMBL-EBI and the Wellcome Trust Sanger Institute was formalised in 2012. EMBL-EBI and the Sanger Institute have shared the Wellcome Genome Campus since 1994 - a proximity that fosters close collaborations and contributes to an international and vibrant working environment.
The EMBL-EBI Industry Programme is a forum for interaction between EMBL-EBI and the industrial life-science research sector. Members include leading pharmaceutical, agribusiness and other companies who engage with EMBL-EBI in the development of services and standards, and collaborate on pre-competitive projects.
Innovative Medicines Initiative projects
Our Industry Programme helps its partners and EMBL-EBI researchers establish collaborations in the context of the Innovative Medicines Initiative.
eTOX: Developing innovative in silico strategies and novel software tools to better predict the toxicological profiles of small molecules in early stages of the drug development pipeline.
EMTRAIN: A platform for education and training covering the whole life cycle of medicines research, from basic science through clinical development to pharmacovigilance.
DDMoRe: The Drug Disease Model Resources consortium: Developing a public drug and disease model library.
EHR4CR: Designing a scalable and cost-effective approach to interoperability between electronic health record systems and clinical research.
EU-AIMS: A large-scale drug-discovery collaboration that brings together academic and industrial R&D with patient organisations to develop and assess novel treatment approaches for autism.
EMIF: Developing a common information framework of patient-level data that will link up and facilitate access to diverse medical and research data sources.
Open PHACTS, the Open Pharmacological Concepts Triple Store: Reducing barriers to drug discovery in industry, academia and for small businesses.